Cyclohexanone is a defined chemical entity of pharmaceutical relevance whose identity, purity, and physicochemical properties are specified per ICH Q6A standards or equivalent pharmacopoeial monograph requirements. Its solubility, lipophilicity, and ionisation state govern formulation compatibility, bioavailability, and environmental distribution behaviour. PDE derivation for Cyclohexanone requires systematic review of acute, repeat-dose, genotoxicity, reproductive toxicity, and carcinogenicity data, identifying the most sensitive adverse effect endpoint and the species-specific NOAEL that forms the point of departure for calculation.
The intraspecies uncertainty factor F2 for Cyclohexanone covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with organ
